Abstract 611P
Background
The ESMO-MCBS provides a standardized assessment of the clinical benefit of a study treatment, considering factors such as overall survival and quality of life. We examined the profile of scores for trials of adjuvant therapy or potentially curative therapies presented at ASCO22 to assess the applicability of the MCBS.
Methods
Abstracts and prior or subsequent (until April 10, 2023) full publications of phase 3 trials on adjuvant therapy or curative treatment presented at ASCO22 were assessed using the MCBS v1.1 evaluation form 1. Scores were calculated based on overall survival, disease free survival or pathological complete response data and graded as A, B or C. Grades A and B indicate a substantial magnitude of clinical benefit. Two independent reviewers performed the grading; discrepancies were resolved through discussion and consensus with a third investigator.
Results
Thirty-five trials were evaluated, of which 11 could not be scored due to insufficient data or endpoint not gradable of the remaining 24 trials, 12 could not be graded due to statistically non-significant results. The remaining 12 trials were scored based on abstract alone (n= 6), or subsequent publication (n=6). A meaningful clinical benefit was seen in 11 of 12 trials (92%) with a score of A (n=9) or B (n=2), whereas 1 study had a score C.
Conclusions
Applying the current ESMO-MCBS to adjuvant and curative phase 3 trials presented at ASCO22 has significant limitations, due to the number of trials not able to be scored. This is a particular problem for studies with non-significant results. Adapting the score to allow grading of all trials may better assist clinicians and patients to assess the value of contemporary research.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
E. Segelov: Non-Financial Interests, Personal, Member: ESMO-MCBS Working Group. All other authors have declared no conflicts of interest.
Resources from the same session
560P - Triple-targeted therapy of dabrafenib, trametinib and osimertinib for the treatment of acquired BRAF V600E mutation after progression on EGFR-TKIs in advanced EGFR-mutant NSCLC
Presenter: Chengdi Weng
Session: Poster Display
Resources:
Abstract
561P - Mechanisms of osimertinib resistance using circulating tumor DNA analyses for EGFR-mutated non-small cell lung cancer, results from ELUCIDATOR: A prospective observational multicenter study
Presenter: Daijiro Harada
Session: Poster Display
Resources:
Abstract
562P - First-line (1L) osimertinib (osi) ± platinum-pemetrexed in patients (pts) with EGFRm advanced NSCLC: FLAURA2 China cohort
Presenter: Yan Yu
Session: Poster Display
Resources:
Abstract
563P - Real-world effectiveness and safety of first-line osimertinib for EGFR-mutated advanced NSCLC in China (FLOURISH study)
Presenter: Jianya Zhou
Session: Poster Display
Resources:
Abstract
564P - Co-occurring EGFR p.E709X mutation affects the treatment response to the third-generation EGFR-TKIs in EGFR p.G719X-mutant patients with advanced NSCLC
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
565P - Genome-guided targeted therapy combination improves survival in patients with advanced EGFR mutation positive NSCLC failing osimertinib
Presenter: Molly Li
Session: Poster Display
Resources:
Abstract
566P - Safety of tepotinib + osimertinib in EGFR-mutant NSCLC with MET amplification after first-line osimertinib
Presenter: Chong Kin Liam
Session: Poster Display
Resources:
Abstract
567P - Furmonertinib in combination with bevacizumab and intrathecal chemotherapy as later-line re-challenge treatment in EGFR –mutated NSCLC patients with leptomeningeal metastasis after third-generation EGFR-TKIs treatment failure
Presenter: Fang Cun
Session: Poster Display
Resources:
Abstract
568P - First-line (1L) osimertinib + platinum-pemetrexed in EGFR-mutated (EGFRm) advanced NSCLC: Updated FLAURA2 safety run-in (SRI) results
Presenter: David Planchard
Session: Poster Display
Resources:
Abstract
569P - Whole-transcriptome sequencing of transformed small-cell lung cancer from EGFR-mutated lung adenocarcinoma reveals LUAD–like and SCLC–like subsets
Presenter: Chan-Yuan Zhang
Session: Poster Display
Resources:
Abstract